# Topical 0.2% Loteprednol Etabonate vs. Topical 0.1% Dexamethasone in Impending Recurrent Pterygium

> **NCT04075227** · PHASE4 · COMPLETED · sponsor: **Wannisa Suphachearabhan** · enrollment: 108 (actual)

## Conditions studied

- Recurrent Pterygium of Eye
- Steroid-Induced Glaucoma

## Interventions

- **DRUG:** 0.2% loteprednol etabonate
- **DRUG:** 0.1% dexamethasone

## Key facts

- **NCT ID:** NCT04075227
- **Lead sponsor:** Wannisa Suphachearabhan
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-10-16
- **Primary completion:** 2019-03-02
- **Final completion:** 2019-03-02
- **Target enrollment:** 108 (ACTUAL)
- **Last updated:** 2019-09-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04075227

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04075227, "Topical 0.2% Loteprednol Etabonate vs. Topical 0.1% Dexamethasone in Impending Recurrent Pterygium". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04075227. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*